Elimination mechanisms of therapeutic monoclonal antibodies

Drug Discovery Today

Volumn 11, Issue 1-2, 2006, Pages 81-88

  Tabrizi, Mohammad A ^a   Tseng, Chih Ming L ^b   Roskos, Lorin K ^a  

^a Abgenix   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTHRACYCLINE; AZATHIOPRINE; BEVACIZUMAB; COMPLEMENT COMPONENT C1Q; CYCLOPHOSPHAMIDE; FC RECEPTOR; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 8 ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PACLITAXEL; PANITUMUMAB; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB;

ANAPHYLAXIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTIGENIC VARIATION; AUTOIMMUNE DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLEMENT ACTIVATION; COMPLEMENTARITY DETERMINING REGION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; EFFECTOR CELL; GENETIC POLYMORPHISM; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN CONSTANT REGION; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOMODULATION; INJECTION SITE REACTION; MOLECULAR MIMICRY; NATURAL KILLER T CELL; NONHUMAN; PSORIASIS; RECEPTOR AFFINITY; REVIEW; RHEUMATOID ARTHRITIS; STEADY STATE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; HUMANS; IMMUNOGLOBULIN G; METABOLIC CLEARANCE RATE;

EID: 32444438731     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03638-X     Document Type: Review

References (55)

1. J. Reichert, A. Pavolu Monoclonal antibodies market Nat. Rev. Drug Discov. 3 2004 383 384
2. L.K. Roskos The clinical pharmacology of therapeutic monoclonal antibodies Drug Dev. Res. 61 2004 108 120
3. E.D. Lobo Antibody pharmacokinetics and pharmacodynamics J. Pharm. Sci. 93 2004 2645 2668
4. L. Tang Pharmacokinetic aspects of biotechnology products J. Pharm. Sci. 93 2004 2184 2204
5. M.D. Hulett, P.M. Hogarth Molecular basis of Fc receptor function Adv. Immunol. 57 1994 1 127
6. A. Morell Serum Concentrations of IgG Subclasses F.H. Bach R.A. Good Clinical Immunobiology 1976 Academic Press 37 56
7. F.W. Brambell The transmission of immunity from mother to young and the catabolism of immunoglobulins Lancet 2 1966 1087 1093
8. V. Ghetie, E.S. Ward FcRn: the MHC class I-related receptor that is more than an IgG transporter Immunol. Today 18 1997 592 598
9. V. Ghetie, E.S. Ward Transcytosis and catabolism of antibody Immunol. Res. 25 2002 97 113
10. R.P. Junghans Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG Immunol. Res. 16 1997 29 57
11. V. Ghetie Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice Eur. J. Immunol. 26 1996 690 696
12. W.F. Dall'Acqua Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences J. Immunol. 169 2002 5171 5180
13. P.R. Hinton Engineered human IgG antibodies with longer serum half-lives in primates J. Biol. Chem. 279 2004 6213 6216
14. M. Raghavan Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants Biochemistry 34 1995 14649 14657
15. R.L. Shields High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R J. Biol. Chem. 276 2001 6591 6604
16. C.K. Borrebaeck Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? Immunol. Today 14 1993 477 479
17. R.J. Ober Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies Int. Immunol. 13 2001 1551 1559
18. K.E. Getman, J.P. Balthasar Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions J. Pharm. Sci. 94 2005 718 729
19. Z. Yu, V.A. Lennon Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases N. Engl. J. Med. 340 1999 227 228
20. T.A. Waldmann Variations in the metabolism of immunoglobulins measured by turnover rates Immunoglobulins: biological aspects and clinical uses 1970 National Academy of Sciences 33 51
21. W.K. Bleeker Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect Blood 98 2001 3136 3142
22. R.J. Hansen, J.P. Balthasar Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor Thromb. Haemost. 88 2002 898 899
23. M.J. Mendez Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice Nat. Genet. 15 1997 146 156
24. X.D. Yang Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states J. Leukoc. Biol. 66 1999 401 410
25. D.A. Mahler Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study Chest 126 2004 926 934
26. J.F. Cohen-Solal Fc gamma receptors Immunol. Lett. 92 2004 199 205
27. M. De Haas IgG-Fc receptors and the clinical relevance of their polymorphisms Wien. Klin. Wochenschr. 113 2001 825 831
28. A. Rascu Clinical relevance of Fc gamma receptor polymorphisms Ann. N. Y. Acad. Sci. 815 1997 282 295
29. J.M. Woof, D.R. Burton Human antibody-Fc receptor interactions illuminated by crystal structures Nat. Rev. Immunol. 4 2004 89 99
30. M. Daeron Fc receptor biology Annu. Rev. Immunol. 15 1997 203 234
31. A.N. Houghton, D.A. Scheinberg Monoclonal antibody therapies - a 'constant' threat to cancer Nat. Med. 6 2000 373 374
32. E.E. Idusogie Engineered antibodies with increased activity to recruit complement J. Immunol. 166 2001 2571 2575
33. L.G. Presta Engineering therapeutic antibodies for improved function Biochem. Soc. Trans. 30 2002 487 490
34. E.S. Ward, V. Ghetie The effector functions of immunoglobulins: implications for therapy Ther. Immunol. 2 1995 77 94
35. R.A. Clynes Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat. Med. 6 2000 443 446
36. G. Cartron Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 2002 754 758
37. G. Cartron From the bench to the bedside: ways to improve rituximab efficacy Blood 104 2004 2635 2642
38. S. Dall'Ozzo Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship Cancer Res. 64 2004 4664 4669
39. B.M. Kumpel Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16) Clin. Exp. Immunol. 132 2003 81 86
40. S.B. Clarkson Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody N. Engl. J. Med. 314 1986 1236 1239
41. T.K. Hart Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys J. Allergy Clin. Immunol. 108 2001 250 257
42. T.K. Hart Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma Clin. Exp. Immunol. 130 2002 93 100
43. Y.S. Lin Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor J. Pharmacol. Exp. Ther. 288 1999 371 378
44. P. Zia-Amirhosseini Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys J. Pharmacol. Exp. Ther. 291 1999 1060 1067
45. J. Mordenti Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins Pharm. Res. 8 1991 1351 1359
46. K. McKeage, C.M. Perry Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2 Drugs 62 2002 209 243
47. E.K. Rowinsky Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer J. Clin. Oncol. 22 2004 3003 3015
48. A. Bunescu Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets J. Rheumatol. 31 2004 2347 2355
49. L.K. Roskos Human Antiglobulin Responses M.T. Lotze A.W. Thompson Measuring Immunity: Basic Science and Clinical Practice 2005 Elsevier Academic Press 172 186
50. M. Clark Antibody humanization: a case of the 'Emperor's new clothes'? Immunol. Today 21 2000 397 402
51. A. Johansson Idiotypic-anti-idiotypic complexes and their in vivo metabolism Cancer 94 2002 1306 1313
52. C.L. Wagner Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade Dev. Biol. (Basel) 112 2003 37 53
53. P.J. Anderson Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles Semin. Arthritis Rheum. 34 2005 19 22
54. C. Pendley Immunogenicity of therapeutic monoclonal antibodies Curr. Opin. Mol. Ther. 5 2003 172 179
55. C.G. Su, G.R. Lichtenstein Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease Gastroenterology 125 2003 1544 1546